Back to Journals » Neuropsychiatric Disease and Treatment » Volume 13

Risperidone-induced reversible neutropenia

Authors Kattalai Kailasam V, Chima V, Nnamdi U, Sharma K, Shah K

Received 10 May 2017

Accepted for publication 16 June 2017

Published 25 July 2017 Volume 2017:13 Pages 1975—1977

DOI https://doi.org/10.2147/NDT.S141472

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Prof. Dr. Roumen Kirov

Peer reviewer comments 2

Editor who approved publication: Dr Roger Pinder


Vasanth Kattalai Kailasam,1 Victoria Chima,2,* Uchechukwu Nnamdi,3,* Kavita Sharma,4,* Kairav Shah5

1College of Medicine, University of Illinois, Chicago, IL, USA; 2Mount Sinai Beth Israel Medical Center, New York, NY, USA; 3Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY, USA; 4Harlem Hospital Center, New York, NY, USA; 5Department of Psychiatry & Behavioral Sciences, The University of Texas McGovern Medical School, Houston, TX, USA

*These authors contributed equally to this work

Abstract: This case report presents a 44-year-old man with a history of schizophrenia who developed neutropenia on risperidone therapy. The patient’s laboratory reports showed a gradual decline of leukocytes and neutrophils after resolution and rechallenging. This was reversed with the discontinuation of risperidone and by switching to olanzapine. In this case report, we also discuss the updated evidence base for management of risperidone-induced neutropenia.

Keywords: risperidone, antipsychotics, neutropenia, blood dyscrasias
 

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]